No mention of Leqembi or Kinsula? Both FDA approved. And Simufilam that was mentioned was cancelled because of a failed phase III study years ago.

But fair, improved biomarker data does not mean the drug is making any real improvements for the patients especially with the side effects. But it is also well known.